MedPath
HSA Product

Spasmolyt Tablet 20mg

Product approved by Health Sciences Authority (SG)

Basic Information

Spasmolyt Tablet 20mg

TABLET, COATED

Regulatory Information

SIN13312P

July 6, 2007

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XG04BD09

Company Information

Madaus GmbH

PHARMLINE MARKETING PTE. LTD.

PHARMLINE MARKETING PTE. LTD.

Active Ingredients

Trospium Chloride

Strength: 20mg

Detailed Information

Contraindications

**Contra-indications** Trospium chloride is contraindicated in patients with urinary retention, severe gastro-intestinal condition (including toxic megacolon), myasthenia gravis, narrowangle glaucoma, and tachyarrhythmia. Trospium chloride is also contraindicated in patients who have demonstrated hypersensitivity to the active substance or to any of the excipients.

Indication Information

**Therapeutic indications** Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder (e.g. idiopathic or neurologic detrusor overactivity).

© Copyright 2025. All Rights Reserved by MedPath